Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.
2.

Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma.

Hassan MS, Awasthi N, Li J, Williams F, Schwarz MA, Schwarz RE, von Holzen U.

Transl Oncol. 2018 Apr;11(2):426-435. doi: 10.1016/j.tranon.2018.01.022. Epub 2018 Feb 20.

3.

Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.

Awasthi N, Monahan S, Stefaniak A, Schwarz MA, Schwarz RE.

Oncotarget. 2017 Dec 25;9(4):5274-5286. doi: 10.18632/oncotarget.23684. eCollection 2018 Jan 12.

4.

Quality measurement affecting surgical practice: Utility versus utopia.

Henry LR, von Holzen UW, Minarich MJ, Hardy AN, Beachy WA, Franger MS, Schwarz RE.

Am J Surg. 2018 Mar;215(3):357-366. doi: 10.1016/j.amjsurg.2017.10.048. Epub 2017 Nov 11. Review.

PMID:
29157888
5.

Institutional variants for lymph node counts after pancreatic resections.

Schwarz RE.

Am J Surg. 2017 Sep;214(3):437-441. doi: 10.1016/j.amjsurg.2017.06.001. Epub 2017 Jun 8.

6.

A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis.

Xiang Z, Zhou ZJ, Xia GK, Zhang XH, Wei ZW, Zhu JT, Yu J, Chen W, He Y, Schwarz RE, Brekken RA, Awasthi N, Zhang CH.

Oncogene. 2017 Sep 7;36(36):5122-5133. doi: 10.1038/onc.2017.108. Epub 2017 May 8.

PMID:
28481874
7.

Vascular challenges from pancreatoduodenectomy in the setting of coeliac artery stenosis.

Beane JD, Schwarz RE.

BMJ Case Rep. 2017 Mar 16;2017. pii: bcr2016217943. doi: 10.1136/bcr-2016-217943.

PMID:
28302657
8.

A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma.

Hassan MS, Awasthi N, Li J, Schwarz MA, Schwarz RE, von Holzen U.

PLoS One. 2017 Feb 22;12(2):e0171824. doi: 10.1371/journal.pone.0171824. eCollection 2017. Erratum in: PLoS One. 2017 Jun 19;12 (6):e0180146.

9.

The impact of immediate breast reconstruction after mastectomy on time to first adjuvant treatment in women with breast cancer in a community setting.

Henry LR, Morris LL, Downs R, Schwarz RE.

Am J Surg. 2017 Mar;213(3):534-538. doi: 10.1016/j.amjsurg.2016.11.004. Epub 2016 Nov 8.

PMID:
27863718
10.

Endothelial Monocyte-Activating Polypeptide II Mediates Macrophage Migration in the Development of Hyperoxia-Induced Lung Disease of Prematurity.

Lee DD, Lal CV, Persad EA, Lowe CW, Schwarz AM, Awasthi N, Schwarz RE, Schwarz MA.

Am J Respir Cell Mol Biol. 2016 Oct;55(4):602-612.

11.

Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.

Awasthi N, Scire E, Monahan S, Grojean M, Zhang E, Schwarz MA, Schwarz RE.

Oncotarget. 2016 Jul 26;7(30):46988-47001. doi: 10.18632/oncotarget.9029.

12.

Profile of nintedanib in the treatment of solid tumors: the evidence to date.

Awasthi N, Schwarz RE.

Onco Targets Ther. 2015 Dec 8;8:3691-701. doi: 10.2147/OTT.S78805. eCollection 2015. Review.

13.

A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases.

Meyer JJ, Foster RD, Lev-Cohain N, Yokoo T, Dong Y, Schwarz RE, Rule W, Tian J, Xie Y, Hannan R, Nedzi L, Solberg T, Timmerman R.

Ann Surg Oncol. 2016 Jan;23(1):218-24. doi: 10.1245/s10434-015-4579-z. Epub 2015 May 12.

14.

The N terminus of pro-endothelial monocyte-activating polypeptide II (EMAP II) regulates its binding with the C terminus, arginyl-tRNA synthetase, and neurofilament light protein.

Xu H, Malinin NL, Awasthi N, Schwarz RE, Schwarz MA.

J Biol Chem. 2015 Apr 10;290(15):9753-66. doi: 10.1074/jbc.M114.630533. Epub 2015 Feb 27.

15.

CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer.

Wei ZW, Xia GK, Wu Y, Chen W, Xiang Z, Schwarz RE, Brekken RA, Awasthi N, He YL, Zhang CH.

Cancer Lett. 2015 Apr 10;359(2):335-43. doi: 10.1016/j.canlet.2015.01.033. Epub 2015 Jan 29.

PMID:
25641338
16.

Current status of management of malignant disease: current management of gastric cancer.

Schwarz RE.

J Gastrointest Surg. 2015 Apr;19(4):782-8. doi: 10.1007/s11605-014-2707-x. Epub 2015 Jan 16. Review.

PMID:
25591828
17.

Experience with a simple clamp-crush technique devoid of other devices for liver resections in a surgical oncology practice.

Schwarz RE.

Am J Surg. 2015 Mar;209(3):503-8. doi: 10.1016/j.amjsurg.2014.09.025. Epub 2014 Dec 13.

PMID:
25557971
18.

Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.

Awasthi N, Hinz S, Brekken RA, Schwarz MA, Schwarz RE.

Cancer Lett. 2015 Mar 1;358(1):59-66. doi: 10.1016/j.canlet.2014.12.027. Epub 2014 Dec 16.

19.

Liver resection for metastatic disease after y90 radioembolization: a case series with long-term follow-up.

Henry LR, Hostetter RB, Ressler B, Bowser I, Yan M, Vaghefi H, Abad J, Gulec S, Schwarz RE.

Ann Surg Oncol. 2015 Feb;22(2):467-74. doi: 10.1245/s10434-014-4012-z. Epub 2014 Sep 5.

PMID:
25190114
20.

Evaluation of skeletonization of the hepatoduodenal ligament for the lower third gastric cancer by propensity score analysis.

Wei ZW, Xia GK, Wu Y, Schwarz RE, Smith DD, He YL, Zhang CH.

Hepatogastroenterology. 2013 Oct;60(127):1789-96.

PMID:
24624453
21.

Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.

Awasthi N, Zhang C, Schwarz AM, Hinz S, Schwarz MA, Schwarz RE.

Mol Cancer Ther. 2014 May;13(5):1032-43. doi: 10.1158/1535-7163.MCT-13-0361. Epub 2014 Mar 7.

22.

Biliary obstruction and postoperative morbidity after pancreatoduodenectomy: what still obstructs clearance to clearance of obstruction.

Schwarz RE.

Am J Surg. 2014 Jul;208(1):11-2. doi: 10.1016/j.amjsurg.2013.12.006. Epub 2014 Jan 16. No abstract available.

PMID:
24560587
23.

Evaluation of para-aortic nodal dissection for locoregionally advanced gastric cancer with 1-3 involved para-aortic nodes.

Zhang C, He Y, Schwarz RE, Smith DD, Wang L, Liu F, Zhan W.

Chin Med J (Engl). 2014;127(3):435-41.

PMID:
24451947
24.

Impact of pre-existing type-2 diabetes on patient outcomes after radical resection for gastric cancer: a retrospective cohort study.

Wei ZW, Li JL, Wu Y, Xia GK, Schwarz RE, He YL, Zhang CH.

Dig Dis Sci. 2014 May;59(5):1017-24. doi: 10.1007/s10620-013-2965-6. Epub 2013 Dec 8.

PMID:
24318804
25.

A comparison of five competing lymph node staging schemes in a cohort of resectable gastric cancer patients.

Smith DD, Nelson RA, Schwarz RE.

Ann Surg Oncol. 2014 Mar;21(3):875-82. doi: 10.1245/s10434-013-3356-0. Epub 2013 Nov 18.

PMID:
24242677
26.

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.

Zhang CΗ, Awasthi N, Schwarz MA, Schwarz RE.

Int J Oncol. 2013 Nov;43(5):1627-35. doi: 10.3892/ijo.2013.2099. Epub 2013 Sep 13.

27.

Is timing to delivery of treatment a reliable measure of quality of care for patients with colorectal adenocarcinoma?

Roland CL, Schwarz RE, Tong L, Ahn C, Balch GC, Yopp AC, Anthony T, Mansour JC.

Surgery. 2013 Sep;154(3):421-8. doi: 10.1016/j.surg.2013.04.049.

PMID:
23972647
28.

Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.

Awasthi N, Zhang C, Schwarz AM, Hinz S, Wang C, Williams NS, Schwarz MA, Schwarz RE.

Carcinogenesis. 2013 Oct;34(10):2361-9. doi: 10.1093/carcin/bgt227. Epub 2013 Jun 26.

29.

Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer.

Wu Y, Wei ZW, He YL, Schwarz RE, Smith DD, Xia GK, Zhang CH.

World J Gastroenterol. 2013 Jun 7;19(21):3309-15. doi: 10.3748/wjg.v19.i21.3309.

30.

PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.

Ostapoff KT, Awasthi N, Cenik BK, Hinz S, Dredge K, Schwarz RE, Brekken RA.

Mol Cancer Ther. 2013 Jul;12(7):1190-201. doi: 10.1158/1535-7163.MCT-12-1123. Epub 2013 May 21.

31.

Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.

Awasthi N, Zhang C, Hinz S, Schwarz MA, Schwarz RE.

J Exp Clin Cancer Res. 2013 Mar 6;32:12. doi: 10.1186/1756-9966-32-12.

32.

Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.

Zhang C, Awasthi N, Schwarz MA, Hinz S, Schwarz RE.

PLoS One. 2013;8(2):e58037. doi: 10.1371/journal.pone.0058037. Epub 2013 Feb 27.

33.

Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.

Peng L, Schwarz RE.

Curr Mol Med. 2013 Mar;13(3):333-9. Review.

PMID:
23331005
34.

Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement.

Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA.

HPB (Oxford). 2013 Feb;15(2):106-15. doi: 10.1111/j.1477-2574.2012.00558.x. Epub 2012 Sep 24.

35.

AHPBA/SSO/SSAT sponsored consensus conference on the multidisciplinary treatment of colorectal cancer metastases.

Schwarz RE, Abdalla EK, Aloia TA, Vauthey JN.

HPB (Oxford). 2013 Feb;15(2):89-90. doi: 10.1111/j.1477-2574.2012.00569.x. No abstract available.

36.

Laparoscopy-assisted resection of proximal gastric cancer: is less than all more or less complete, or is all more, nonetheless?

Schwarz RE, Zhang C, Mansour JC.

Gastric Cancer. 2013 Jul;16(3):277-9. doi: 10.1007/s10120-012-0222-x. No abstract available.

PMID:
23247699
37.

Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer.

Zhang C, Awasthi N, Schwarz MA, Schwarz RE.

J Surg Res. 2013 Jun 15;182(2):227-34. doi: 10.1016/j.jss.2012.10.052. Epub 2012 Nov 15.

PMID:
23201270
38.

BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.

Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.

Mol Cancer Ther. 2012 Dec;11(12):2644-53. doi: 10.1158/1535-7163.MCT-12-0447. Epub 2012 Oct 9.

39.

Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection.

Yopp AC, Subramanian M, Jain MK, Mansour JC, Schwarz RE, Balch GC, Singal AG.

Clin Gastroenterol Hepatol. 2012 Nov;10(11):1284-90. doi: 10.1016/j.cgh.2012.08.010. Epub 2012 Aug 16.

40.

Rare hepatic arterial anatomic variants in patients requiring pancreatoduodenectomy and review of the literature.

Ramanadham S, Toomay SM, Yopp AC, Balch GC, Sharma R, Schwarz RE, Mansour JC.

Case Rep Surg. 2012;2012:953195. doi: 10.1155/2012/953195. Epub 2012 Jul 30.

41.

Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.

Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, Schwarz RE, Burrows FJ, Brekken RA.

Clin Cancer Res. 2012 Sep 15;18(18):5031-42. doi: 10.1158/1078-0432.CCR-12-0453. Epub 2012 Jul 24.

42.

Collision tumor in form of primary adenocarcinoma and neuroendocrine carcinoma of the duodenum.

Peng L, Schwarz RE.

Rare Tumors. 2012 Apr 12;4(2):e20. doi: 10.4081/rt.2012.e20.

43.

Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.

Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.

PLoS One. 2012;7(6):e38477. doi: 10.1371/journal.pone.0038477. Epub 2012 Jun 18.

44.

Clinical Evidence: Metastases can Metastasize.

Stanley GA, Balani JP, Miller DS, Mansour JC, Schwarz RE.

World J Oncol. 2012 Jun;3(3):138-141. doi: 10.4021/wjon406w. Epub 2012 Jul 5.

45.

The real estate of gastric cancer induction therapy: location versus intrinsic molecular architecture.

Schwarz RE, Mansour JC.

Ann Surg Oncol. 2012 Jul;19(7):2081-3. doi: 10.1245/s10434-012-2366-7. No abstract available.

PMID:
22535261
46.

Intraduodenal sarcoma recurrence of retroperitoneal origin: an unusual cause for a duodenal obstruction.

Bao JJ, Mansour JC, Timmerman RD, Kirane A, Ewing GE, Schwarz RE.

World J Surg Oncol. 2012 Apr 20;10:59. doi: 10.1186/1477-7819-10-59.

47.

Routine nasogastric decompression is unnecessary after pancreatic resections.

Roland CL, Mansour JC, Schwarz RE.

Arch Surg. 2012 Mar;147(3):287-9. doi: 10.1001/archsurg.2011.1260.

PMID:
22430915
48.

Cell proliferation and migration are modulated by Cdk-1-phosphorylated endothelial-monocyte activating polypeptide II.

Schwarz MA, Thornton J, Xu H, Awasthi N, Schwarz RE.

PLoS One. 2012;7(3):e33101. doi: 10.1371/journal.pone.0033101. Epub 2012 Mar 8.

49.

Obesity and postgastrectomy outcomes: large risks, fat chances, or no big deal?

Schwarz RE.

Gastric Cancer. 2012 Apr;15(2):121-3. doi: 10.1007/s10120-012-0144-7. No abstract available.

PMID:
22350826
50.

Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancreatic cancer.

Heinzerling JH, Bland R, Mansour JC, Schwarz RE, Ramirez E, Ding C, Abdulrahman R, Boike TP, Solberg T, Timmerman RD, Meyer JJ.

Radiat Oncol. 2011 Oct 28;6:146. doi: 10.1186/1748-717X-6-146.

Supplemental Content

Loading ...
Support Center